It is typically taken along with dietary and lifestyle changes.
Therefore, you may be prescribed Zepbound over Mounjaro if you are seeking obesity treatment and qualify.
Is Mounjaro a Weight Loss Medication?
Getty Images /Bloomberg/ Contributor
Currently, the FDA has not approved Mounjaro for weight loss specifically.
It has only approved it for controlling blood sugar in adults with pop in 2 diabetes.
Are Mounjaro and Zepbound the Same?
Mounjaro and Zepbound both contain the same active ingredient, tirzepatide.
However, this does not necessarily mean they are interchangeable.
Mounjaro is specifically FDA-approved for people with throw in 2 diabetes.
Zepbound, on the other hand, is FDA-approved for weight loss.
Because they are approved for different uses, insurance coverage for each may differ.
Does It Work?
This study helped to show tirzepatides effectiveness in providing significant and sustained weight loss in people with obesity.
How Does Mounjaro Work for Weight Loss?
In contrast, those who switched to the placebo regained most of the lost weight.
How Does Mounjaro Compare to Ozempic?
The manufacturer of Ozempic, Novo Nordisk, also developed a drug specifically for weight loss, calledWegovy.
Wegovy also contains semaglutide, the same ingredient in Ozempic.
People using tirzepatide had a more significant reduction in hemoglobin A1C than those on semaglutide.
Additionally, Mounjaro led to more significant weight loss compared to Ozempic.
Overall, Mounjaro was more effective, leading to better weight loss benefits than Ozempic did.
If you have symptoms of an allergic reaction, you should get emergency medical help.
The warning states that Mounjaro has caused thyroid tumors in animal studies.
Whether this risk applies to humans is unknown.
Some of the most common side effects of tirzepatide include nausea, vomiting, and diarrhea.
DailyMed.Mounjaro- tirzepatide injection, solution.
U.S. Food and Drug Administration.FDA approves new medication for chronic weight management.
U.S. Food and Drug Administration.Fast Track.
2022;387(3):205-216. doi:10.1056/NEJMoa2206038
MedlinePlus.Tirzepatide injection.
